Pharmafile Logo

News and Press Releases

Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types

Aggregate analysis of eight clinical trials of patients with advanced non-small cell lung cancer (aNSCLC) was supported by Biodesix, using Bio-Rad Droplet Digital™ PCR technology 23 April 2025 -- Colorado,...

Category: BioManufacturing, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 23, 2025

Biodesix
919 W Dillon Rd, Louisville, CO 80027

Liverpool City Region set to become global powerhouse in new front for fighting disease and driving wellbeing

23 April 2025 -- Liverpool, UK -- Liverpool City Region is set to become a global powerhouse in a new front to tackle deadly diseases and improve wellbeing. More than...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 23, 2025

The University of Liverpool
Foundation Building Brownlow Hill Liverpool L69 7ZX

Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers

23 April 2025 -- Ingelheim, Germany and Amsterdam, the Netherlands -- Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: April 23, 2025

Boehringer Ingelheim
Binger Strasse 173 55216 Ingelheim am Rhein

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China

22 April 2025 -- Hong Kong, Shanghai and New Jersey, US -- HUTCHMED today announces that it has completed enrollment of the registration phase of its Phase II trial of...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 22, 2025

HUTCHMED
48th Floor, Cheung Kong Center 2 Queen's Road Central, Hong Kong

US FDA Grants Qualified Infectious Disease Product Designation to Venus Remedies’ VRP-034, a Novel Polymyxin B Formulation

VRP-034 is a novel supramolecular cationic (SMC) formulation of polymyxin B sulphate, uniquely developed to mitigate the nephrotoxic effects associated with conventional polymyxin B (PMB) therapy Key preclinical findings for...

Category: Biotechnology, Clinical Trials, Drug Delivery, Other, Pharmaceutical
Posted: April 17, 2025

Venus Remedies
info@venusremedies.com, bd@venusremedies.com
51-52, Industrial Area Phase-1, Panchkula, Haryana, 134113

Blenrep (belantamab mafodotin) combinations approved by UK MHRA in relapsed/refractory multiple myeloma 

Superior efficacy shown in two head-to-head phase III trials, including overall survival in DREAMM-7 Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed UK...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 17, 2025

GSK
980 Great West Rd, London TW8 9GS

Moderna’s UK Manufacturing Facility Receives Manufacturing Licence from the MHRA

Milestone marks a pivotal step toward producing mRNA vaccines in the UK in 2025 15 April 2025 – London, UK – ACCESS WIRE – Moderna, Inc. (NASDAQ: MRNA) today announced...

Category: Manufacturing and Packing
Posted: April 15, 2025

Moderna
info@modernatx.com
Global Headquarters 200 Technology Square Cambridge, MA 02139

Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Interim blinded safety and pharmacokinetic data to be presented at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) 10 April 2025 -- Maryland, US...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 10, 2025

Theriva Biologics
info@therivabio.com
9605 Medical Center Dr. Suite 270 Rockville, MD 20850

ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch

7 April 2025 -- California, US -- ImmunityBio, Inc, a leading immunotherapy company, today announced details about its Investor Day program to be held on Tuesday, April 15, 2025, at...

Category: Drug Discovery, Other, Pharmaceutical
Posted: April 7, 2025

ImmunityBio
info@ImmunityBio.com
3530 John Hopkins Court San Diego, CA 92121

European Commission approves subcutaneous RYBREVANT▼ (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer

Subcutaneous (SC) amivantamab offers patients greater convenience, reducing administration time from hours to minutes and with a five-fold reduction in infusion-related reactions compared to the IV formulation European Commission (EC) approval based on positive...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 7, 2025

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

Epsilogen Announces Acquisition of TigaTx, Inc. to Create World’s Leading Pan-Isotype Cancer Antibody Company

The acquisition combines IgA antibody assets and expertise of Boston-based TigaTx with Epsilogen’s assets and expertise in IgE to create the world’s leading pan-isotype cancer antibody company Allows selection of...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 7, 2025

Epsilogen
info@epsilogen.com
Waterfront, ARC West London, Manbre Road, Hammersmith, London, W6 9RH

Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines

Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease Rilzabrutinib is currently under regulatory review in the US, EU and China for potential use in immune thrombocytopenia.  3 April...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 3, 2025

Sanofi
One Onslow Street, Guildford, Surrey, GU1 4YS, UK

Astellas and Japanese Foundation for Cancer Research Announce Collaboration to Accelerate Translational and Clinical Oncology Research

Initial collaboration will support projects of mutual interest and help accelerate advancement of Astellas’ early-stage oncology pipeline 2 April 2025 -- Tokyo, Japan -- Astellas Pharma Inc and Japanese Foundation...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 2, 2025

Astellas
2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, Japan

Navigo Proteins Announces Strategic R&D Collaboration with SCK CEN to Develop Targeted Radiotheranostics

1 April 2025 -- Halle, Germany and Mol, Belgium -- Navigo Proteins GmbH, a leader in precision medicine and next-generation radiotheranostics, today announced a strategic research collaboration with SCK CEN,...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: April 1, 2025

Navigo Proteins
info@navigo-proteins.com
Heinrich-Damerow-Strasse 1 06120 Halle Germany

Domain Therapeutics to Present Data on its GPCR Lead Programs at AACR Annual Meeting 2025

Presentation of Phase I clinical results from DT-9081, an EP4 receptor antagonist, and preclinical data on DT-7012, a Treg depleting anti-CCR8 antibody Preclinical findings highlight immuno-oncology breakthrough properties for its...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 1, 2025

Domain Therapeutics
contact@domaintherapeutics.com
PARC D'INNOVATION 220 Boulevard Gonthier D'Andernach 67400 Strasbourg - Illkirch - France